Bragar Eagel & Squire, P.C. Is Investigating JinkoSolar, Integra, and Chinook and Encourages Investors to Contact the Firm

Advertisement

NEW YORK, June 09, 2023 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against JinkoSolar Holding Co., Ltd. (NYSE: JKS), Integra LifeSciences Holdings Corp. (NASDAQ: IART), and Chinook Therapeutics, Inc. (NASDAQ: KDNY). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

JinkoSolar Holding Co., Ltd. (NYSE: JKS)

On May 8, 2023, federal agents executed a search warrant at JinkoSolar’s solar panel manufacturing plant in Jacksonville, Florida. Federal authorities did not disclose the specific reason for the search warrant.

Advertisement

On this news, JinkoSolar’s stock price fell $3.91 per share, or 8.25%, to close at $43.47 per share on May 9, 2023.

For more information on the JinkoSolar investigation go to: https://bespc.com/cases/JKS

Integra LifeSciences Holdings Corp. (NASDAQ: IART)

On May 23, 2023, Integra disclosed that it had initiated a recall of its SurgiMed, PriMatrix, Revize, and TissueMend products manufactured at its Boston facility as far back as March 1, 2018. The Company attributed the recall to a finding that products may have been distributed with higher levels of endotoxins than permitted by the product specifications. As a result, the Company expects to write off approximately $22 million in inventory.

On this news, Integra’s stock price fell $10.24, or 20.2%, to close at $40.48 per share on May 23, 2023, thereby injuring investors. 

For more information on the Integra investigation go to: https://bespc.com/cases/IART

Chinook Therapeutics, Inc. (NASDAQ: KDNY)

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Chinook is the subject of a report issued by Muddy Waters Research on May 16, 2023. According to the report, the Company’s lead product candidate “has been shown to be harmful to patients’ cardiovascular health”, and that “AbbVie and Chinook seem to have systemically manipulated research findings and presentation on atrasentan to obscure these trial results.” 

On this news, shares of Chinook fell by almost 4.5% on the same day.

For more information on the Chinook investigation go to: https://bespc.com/cases/KDNY

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
[email protected]
www.bespc.com

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.